Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr Wisinski on Treatment Developments in HR+/HER2– Breast Cancer

February 29th 2024

Kari Wisinski, MD, discusses treatment development and the current arsenal for patients with hormone receptor–positive, HER2-negative breast cancer.

Clinical Scenario: A 57-Year-Old Woman With Metastatic Breast Cancer

February 29th 2024

Two oncologists present the clinical scenario of a 57-year-old woman with metastatic HER2-positive breast cancer to discuss their approach for incorporating recent research into clinical decision making around systemic therapy.

Ongoing Studies in Genomic Testing for Breast Cancer

February 27th 2024

Closing their discussion, experts share ongoing studies utilizing genomic testing for patients with breast cancer.

Reflecting on Genomic Testing in Practice for Breast Cancer

February 27th 2024

Joyce O’Shaughnessy, MD and Erin Cobain, MD, offer their reflections of genomic testing in breast cancer and its impact on clinical practice.

Revisit Every OncLive On Air Episode From January 2024

February 26th 2024

In case you missed it, read a recap of every episode of OncLive On Air recorded in January 2024.

Exciting Ongoing Studies in the Treatment of HR+, HER2- Metastatic Breast Cancer

February 23rd 2024

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

Dr Jagsi on the Feasibility of Radiation Omission Following Surgery in Breast Cancer Care

February 22nd 2024

Reshma Jagsi, MD, DPhil, discusses 5-year findings from the IDEA trial assessing radiotherapy omission for postmenopausal patients with breast cancer.

Currently Enrolling Trial Examines Innovative Approach in Inflammatory Breast Cancer

February 21st 2024

The S1706 study is currently enrolling patients with inflammatory breast cancer to determine if adding a PARP inhibitor to radiation therapy is effective.

Dr Meisel on Patient-Reported Perceptions of Provider Communication in Breast Cancer Care

February 20th 2024

Jane L. Meisel, MD, discusses patient-reported perceptions of patient-provider communication in cancer care.

Racial Disparities and Genomic Testing for Breast Cancer Patients

February 20th 2024

Dr O’Shaughnessy and Dr Cobain review growing discussions from SABCS 2023 surrounding the impact of racial disparities and genomic testing for breast cancer patients.

Real-World Evidence in Genomic Testing from SABCS 2023

February 20th 2024

Experts in breast cancer outline data presented at SABCS 2023, focusing on real-world evidence for genomic assays used in practice.

Patient Toxicity and QOL Concerns Must Be Considered in Breast Cancer Treatment Decision-Making

February 19th 2024

Jane L. Meisel, MD, discusses the importance of prioritizing patients’ toxicity concerns and quality of life in the management of breast cancer.

Dr Advani on the Evaluation of Ribociclib/Endocrine Therapy in HR+/HER2– Breast Cancer

February 16th 2024

Pooja Advani, MBBS, MD, discusses the use of ribociclib plus endocrine therapy for patients with hormone receptor–positive, HER2– breast cancer.

Jagsi Holds a Magnifying Glass to Radiation Oncology: Uncovering Key Disparities and When to Omit Radiation in Breast Cancer

February 16th 2024

Investigating when radiation therapy can be appropriately omitted and striving to uncover disparities are areas of focus in the field of radiation oncology.

Approaches to Treatment Decision-Making and Sequencing for HR+, HER2- Metastatic Breast Cancer

February 16th 2024

The TROPION-Breast01 Trial: Datopotamab Deruxtecan in HR+, HER2- Breast Cancer

February 16th 2024

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

Dr Advani on the Advantages of Liquid Biopsy in Metastatic Breast Cancer

February 14th 2024

Pooja Advani, MBBS, MD, discusses the advantages of using liquid biopsy in metastatic breast cancer.

Exploring Multigene Genomic Assays in High-Risk BC Patients

February 13th 2024

Dr. O’Shaughnessy details the genomic assay MammaPrint and how it compares to other multigene assays used in practice, highlighting the MINDACT and TAILORx trials.

FLEX Trial: Genomic Testing of HER2 Status in ER+/HER2-Breast Cancer

February 13th 2024

Expert oncologists discuss genomic testing for patients with HER2-low breast cancer, noting the FLEX trial of MammaPrint and BluePrint.

Omission in Breast Cancer: When to Leave Radiation Behind and How to Mitigate Disparities

February 12th 2024

Reshma Jagsi, MD, DPhil, details advances from 2023 in breast cancer radiation oncology and interventions aimed at combating disparities within oncology.